Pemphigus Vulgaris Market Size (7MM) is going to be ~USD 360 million in 2025, and expected to grow with a CAGR of 3.6% during the forecast period (2025-2034) | DelveInsight

(Albany, USA) DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Explore In-depth insights into the evolving Pemphigus Vulgaris Market. Download sample report @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pemphigus Vulgaris Market Report
• Among the 7MM, the United States accounted for the highest number of cases of Pemphigus Vulgaris in 2023, with nearly 40,000 cases. These cases are anticipated to increase by 2034.
• In the United States, individuals of the 60-69 year age group account for the highest number of cases of Pemphigus Vulgaris in 2023.
• In the 7MM, the prevalence of females is more than males in Pemphigus Vulgaris.
• Among EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases in 2023, while Spain accounted for the least.
• The leading Pemphigus Vulgaris Companies such as Roche, Cabaletta Bio and others.
• Promising Pemphigus Vulgaris Therapies such as PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others.

Explore Pemphigus Vulgaris Treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pemphigus Vulgaris Epidemiology Segmentation in the 7MM
• Total Pemphigus Vulgaris Diagnosed prevalent cases
• Pemphigus Vulgaris Gender-specific cases
• Pemphigus Vulgaris Age-specific cases
• Pemphigus Vulgaris Severity-specific cases
• Total Pemphigus Vulgaris Treated cases

Download the report to understand which factors are driving Pemphigus Vulgaris Epidemiology trends @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Pemphigus Vulgaris Therapies
• RITUXAN (rituximab): Roche
RITUXAN (rituximab) is the only FDA-approved therapy for the treatment of pemphigus vulgaris. It serves as a key treatment, especially for moderate to severe cases. As the first biologic therapy approved by the FDA for this condition, RITUXAN represents a significant advancement in over 60 years. The FDA has granted RITUXAN several important designations, including Priority Review, Breakthrough Therapy Designation, and Orphan Drug Designation, emphasizing its critical role in treating Pemphigus Vulgaris. Rituximab is a CD20-directed cytolytic antibody that targets B-cells, which are responsible for producing the autoantibodies that attack the skin and mucous membranes in Pemphigus Vulgaris. By depleting these B-cells, RITUXAN reduces the production of harmful antibodies, leading to improved symptoms and better disease control.

Emerging Pemphigus Vulgaris Therapies
• CABA-201 (4-1BB CD19-CAR T): Cabaletta Bio
CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, which may enable an "immune system reset" with the potential for durable remission of therapy in patients with autoimmune diseases. To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions, including Systemic Lupus Erythematosus (SLE), myositis, systemic sclerosis and generalized Myasthenia Gravis (gMG). Cabaletta is conducting four RESET Phase I/II clinical trials with a total of nine cohorts that can advance simultaneously, employing a similar parallel cohort design and starting dose of 1 x 106 cells/kg without a dose escalation requirement. In January 2020, Cabaletta Bio announced that the US Food and Drug Administration (FDA) had granted an Orphan Drug Designation for the Company's lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris.

Pemphigus Vulgaris Treatment Landscape
The treatment of Pemphigus Vulgaris has significantly improved with the use of systemic corticosteroids, which reduced the disease's mortality rate by 60%. These steroids remain the first-line therapy, particularly for mild cases, though they require careful monitoring due to side effects like infections and osteoporosis. For moderate-to-severe PV, rituximab, an anti-CD20 monoclonal antibody, is commonly used in combination with corticosteroids, helping to deplete B-cells responsible for producing the autoantibodies that attack the skin. Steroid-sparing agents like azathioprine and mycophenolate mofetil (MMF) are also used to reduce steroid dependence and minimize side effects. For refractory cases, treatments such as IVIg and cyclophosphamide may be considered. While these therapies have improved outcomes, Pemphigus Vulgaris treatment remains complex, requiring ongoing management to balance efficacy and side effects.

Get In-Depth Knowledge on Pemphigus Vulgaris Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pemphigus Vulgaris Companies
Roche, Cabaletta Bio and others.

Pemphigus Vulgaris Market Outlook
Currently, RITUXAN (rituximab) is the only FDA-approved therapy for the treatment of pemphigus vulgaris. It serves as a key treatment, especially for moderate to severe cases. As the first biologic therapy approved by the FDA for this condition, RITUXAN represents a significant advancement in over 60 years. A CD19-CAR T-cell therapy is being developed by Cabaletta Bio for treating autoimmune diseases, including Pemphigus Vulgaris. Currently, in mid-stage development, CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, potentially enabling an "immune system reset" and durable disease remission. Cabaletta has received FDA clearance for Investigational New Drug (IND) applications for CABA-201 in several autoimmune conditions, and the therapy is being tested in multiple RESET Phase I/II clinical trials.

Pemphigus Vulgaris Drugs Uptake
This section focuses on the rate of uptake of the potential Pemphigus Vulgaris drugs expected to be launched in the market during the study period. The analysis covers Pemphigus Vulgaris market uptake by drugs patient uptake by therapies; and sales of each product.

Get In-Depth Knowledge on Pemphigus Vulgaris Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pemphigus Vulgaris Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Pemphigus Vulgaris Companies- Roche, Cabaletta Bio and others.
• Pemphigus Vulgaris Therapies- PRN1008, Mycophenolate Mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273, and others.
• Pemphigus Vulgaris Therapeutic Assessment: Pemphigus Vulgaris Current marketed and Pemphigus Vulgaris emerging therapies
• Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers
• Pemphigus Vulgaris Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pemphigus Vulgaris Unmet Needs, KOL's views, Analyst's views, Pemphigus Vulgaris Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Pemphigus Vulgaris Market Report @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Pemphigus Vulgaris Market Overview at a Glance
4. Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Pemphigus Vulgaris Treatment and Management
9. Pemphigus Vulgaris Epidemiology and Patient Population
10. Pemphigus Vulgaris Patient Journey
11. Emerging Pemphigus Vulgaris Therapies
12. Pemphigus Vulgaris Market Analysis
13. Pemphigus Vulgaris KOL Views
14. Pemphigus Vulgaris SWOT Analysis
15. Pemphigus Vulgaris Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.